Citation tools
"The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at
5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the
Activity of Frontocortical Dopaminergic and Adrenergic Pathways." Journal of Pharmacology and Experimental Therapeutics
306.3
(2003):
954-964.
Web. 19 Mar. 2024.